- Home
- VRAR vs KZR Comparison
VRAR vs KZR Comparison
Compare VRAR & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- KZR
- Stock Information
- Founded
- VRAR 2016
- KZR 2015
- Country
- VRAR United States
- KZR United States
- Employees
- VRAR N/A
- KZR N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- VRAR Technology
- KZR Health Care
- Exchange
- VRAR Nasdaq
- KZR Nasdaq
- Market Cap
- VRAR 29.1M
- KZR 29.7M
- IPO Year
- VRAR 2021
- KZR 2018
- Fundamental
- Price
- VRAR $1.13
- KZR $6.20
- Analyst Decision
- VRAR Strong Buy
- KZR Hold
- Analyst Count
- VRAR 1
- KZR 4
- Target Price
- VRAR $2.62
- KZR $6.00
- AVG Volume (30 Days)
- VRAR 137.0K
- KZR 83.3K
- Earning Date
- VRAR 11-13-2025
- KZR 11-12-2025
- Dividend Yield
- VRAR N/A
- KZR N/A
- EPS Growth
- VRAR N/A
- KZR N/A
- EPS
- VRAR N/A
- KZR N/A
- Revenue
- VRAR $9,488,209.00
- KZR N/A
- Revenue This Year
- VRAR $15.29
- KZR N/A
- Revenue Next Year
- VRAR $44.54
- KZR N/A
- P/E Ratio
- VRAR N/A
- KZR N/A
- Revenue Growth
- VRAR 16.60
- KZR N/A
- 52 Week Low
- VRAR $0.50
- KZR $3.53
- 52 Week High
- VRAR $7.00
- KZR $7.65
- Technical
- Relative Strength Index (RSI)
- VRAR 33.19
- KZR 71.39
- Support Level
- VRAR $1.39
- KZR $6.07
- Resistance Level
- VRAR $1.43
- KZR $6.30
- Average True Range (ATR)
- VRAR 0.13
- KZR 0.14
- MACD
- VRAR -0.04
- KZR -0.07
- Stochastic Oscillator
- VRAR 12.90
- KZR 78.12
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.